Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Return on Equity (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Return on Equity for 7 consecutive years, with 2.8% as the latest value for Q4 2025.

  • Quarterly Return on Equity changed N/A to 2.8% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.8% through Dec 2025, changed N/A year-over-year, with the annual reading at 0.95% for FY2023, 46.0% down from the prior year.
  • Return on Equity for Q4 2025 was 2.8% at Actinium Pharmaceuticals, down from 2.41% in the prior quarter.
  • The five-year high for Return on Equity was 0.19% in Q2 2021, with the low at 2.8% in Q4 2025.
  • Average Return on Equity over 5 years is 0.97%, with a median of 0.87% recorded in 2023.
  • The sharpest move saw Return on Equity rose 6bps in 2024, then crashed -141bps in 2025.
  • Over 5 years, Return on Equity stood at 0.32% in 2021, then crashed by -53bps to 0.5% in 2022, then plummeted by -149bps to 1.23% in 2023, then increased by 19bps to 1.0% in 2024, then crashed by -181bps to 2.8% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 2.8%, 2.41%, and 2.05% for Q4 2025, Q3 2025, and Q2 2025 respectively.